Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
Public ClinicalTrials.gov record NCT02531438. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Study identification
- NCT ID
- NCT02531438
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 774 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2015 (Actual)
- Primary completion
- Feb 5, 2017 (Actual)
- Completion
- Mar 10, 2017 (Actual)
- Last update posted
- Jan 16, 2019
2015 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 514 | Birmingham | Alabama | 35215 | — |
| Site 501 | Mobile | Alabama | 36608 | — |
| Site 508 | Laguna Hills | California | 92653 | — |
| Site 505 | Ventura | California | 93003 | — |
| Site 513 | Stamford | Connecticut | 06902 | — |
| Site 511 | Zachary | Louisiana | 70791 | — |
| Site 503 | Detroit | Michigan | 48202 | — |
| Site 520 | Saint Paul | Minnesota | 55101 | — |
| Site 512 | St Louis | Missouri | 63110 | — |
| Site 506 | Buffalo | New York | 14215 | — |
| Site 509 | Dayton | Ohio | 45409 | — |
| Site 516 | Huntington | West Virginia | 25701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02531438, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2019 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02531438 live on ClinicalTrials.gov.